Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection
Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection
复制标题
DOI:
10.1016/j.cmi.2020.05.036
复制
发表时间:
2020-09-01
影响因子:
14.2
通讯作者:
Sethi, S. K.
中科院分区:
文献类型:
--
作者:
Chew, K. L.;Tan, S. S.;Sethi, S. K.
Objective: This study aimed to evaluate the diagnostic performance of the Abbott Architect SARS-CoV-2 IgG assay in COVID-19 patients.Methods: Residual sera from 177 symptomatic SARS-CoV-2-positive patients and 163 non-COVID-19 patients were tested for antibody with the Abbott SARS-CoV-2 IgG assay (Abbott Diagnostics, Chicago, USA). Clinical records for COVID-19 patients were reviewed to determine the time from onset of clinical illness to testing.Results: Specificity of the assay was 100.0% (95%CI: 97.1-100.0%). The clinical sensitivity of the assay varied depending on time from onset of symptoms, increasing with longer periods from the onset of clinical illness. The clinical sensitivity at = 21 days 84.4% (27/ 32; 95%CI: 66.5-94.1%). Clinical sensitivity was higher in the >= 14-day group compared to = 21-days groups; the combined clinical sensitivity for these groups (>= 14 days) was 84.2% (49/57; 71.6e92.1%).Conclusion: The Abbott SARS-CoV-2 IgG test has high specificity. Clinical sensitivity was limited in the early stages of disease but improved from 14 days after the onset of clinical symptoms. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.